Related Experiment Video
Updated: Dec 9, 2025
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Development of a Novel Class of Self-Assembling dsRNA Cancer Therapeutics: A Proof-of-Concept Investigation
Vishwaratn Asthana1, Brett S Stern1, Yuqi Tang1
1Department of Bioengineering, Rice University, Houston, TX 77030, USA.
Abstract:
Cancer has proven to be an extremely difficult challenge to treat. Several fundamental issues currently underlie cancer treatment, including differentiating self from nonself, functional coupling of the recognition and therapeutic components of various therapies, and the propensity of cancerous cells to develop resistance to common treatment modalities via evolutionary pressure. Given these limitations, there is an increasing need to develop an all-encompassing therapeutic that can uniquely target malignant cells, decouple recognition from treatment, and overcome evolutionarily driven cancer resistance. We describe herein a new class of programmable self-assembling double-stranded RNA (dsRNA)-based cancer therapeutics that uniquely targets aberrant genetic sequences and in a functionally decoupled manner, undergoes oncogenic RNA-activated displacement (ORAD), initiating a therapeutic cascade that induces apoptosis and immune activation. As a proof of concept, we show that RNA strands targeting the EWS/Fli1 fusion gene in Ewing sarcoma cells that are end blocked with phosphorothioate bonds and additionally sealed with a 2'-deoxyuridine (2'-U)-modified DNA protector can be used to induce specific and potent killing of cells containing the target oncogenic sequence but not wild type.
Insights
This study introduces novel double-stranded RNA (dsRNA) cancer therapeutics. These programmable agents target specific cancer genes, triggering cell death and immune responses while overcoming treatment resistance.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Cancer treatment faces challenges in distinguishing self from non-self cells, integrating therapeutic and recognition functions, and overcoming drug resistance.
- Existing therapies are limited by cancer cells' ability to evolve resistance through evolutionary pressure.
Purpose of the Study:
- To develop a novel, programmable, self-assembling double-stranded RNA (dsRNA)-based therapeutic platform for cancer.
- To create a treatment that uniquely targets malignant cells, decouples recognition from therapy, and overcomes drug resistance.
Main Methods:
- Designed programmable self-assembling dsRNA therapeutics targeting specific aberrant genetic sequences.
- Utilized oncogenic RNA-activated displacement (ORAD) for a functionally decoupled therapeutic cascade.
- Employed end-blocked RNA strands with phosphorothioate bonds and 2'-deoxyuridine (2'-U)-modified DNA protectors.
Main Results:
- Demonstrated specific and potent killing of cancer cells harboring the target oncogenic sequence (EWS/Fli1 fusion gene in Ewing sarcoma).
- Showed no significant effect on cells with wild-type sequences, confirming target specificity.
- Initiated apoptosis and immune activation through the ORAD mechanism.
Conclusions:
- Programmable dsRNA therapeutics offer a promising new modality for cancer treatment.
- The ORAD mechanism provides a unique approach to cancer therapy, decoupling recognition and treatment.
- This platform has the potential to overcome evolutionarily driven cancer resistance and improve therapeutic outcomes.
More Related Videos
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
09:18TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
Published on: June 2, 2016
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...